France
Every company in the roster headquartered in France.
Every company in the roster headquartered in France.
16 of 16 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
SanofiSNY · Nasdaq | 63 assets: 23 approved, 8 Ph 3, 12 Ph 2, 5 Ph 1, 15 other | GemigliptinPhase 3 · Type 2 DiabetesReliable signal | 25 Nov 2026rilzabrutinib · Phase 3 | $113.5B | $6.3BMar 2026 | — | $9.0B |
AbivaxABVX · Nasdaq | 1 asset: 1 Ph 3 | obefazimodPhase 3 · Ulcerative ColitisReliable signal | Dec 2026obefazimod · Phase 2 | $7.3B | $460MJun 2026 | ~13.8 qtrswith a later raise | $216M |
InventivaIVA · Nasdaq | 1 asset: 1 Ph 3 | LanifibranorPhase 3 · MASH / NASHPartial signal | None on record | $655M | $100MDec 2024 | ~9.1 qtrswith a later raise | $98M |
AB ScienceAB · Euronext Paris | 2 assets: 1 Ph 3, 1 Ph 2 | MasitinibPhase 3 · Alzheimer's DiseaseReliable signal | Dec 2027Masitinib · Phase 3 | — | $10MJun 2026 | ~5.6 qtrswith a later raise | ~$20M |
AdociaADOC · Euronext Paris | 1 asset: 1 Ph 3 | THDB0206Phase 3 · Type 2 DiabetesPartial signal | None on record | — | — | — | — |
MedincellMEDCL · Euronext Paris | 2 assets: 2 approved | Approved assets only | None on record | — | — | — | — |
NanobiotixNBTX · Nasdaq | 1 asset: 1 Ph 3 | NBTXR3Phase 3 · Head and Neck Squamous Cell Carcinoma | 30 Apr 2027NBTXR3 · Phase 1 | — | $62MDec 2025 | ~6.5 qtrs | $26M |
Advanced BioDesignPrivate | 1 asset: 1 Ph 2 | ABD-3001Phase 1/2 · Acute Myeloid Leukemia | None on record | — | — | — | — |
Laboratoire X.OPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
| 2 assets: 2 approved | Approved assets only | Aug 2028Ponesimod · Phase 3 | — | — | — | — | |
Laboratoires ThéaPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Orano Med Theranostics, SASPrivate | 1 asset: 1 Ph 1 | Pb-DOTAM-GRPR1Phase 1 · Non-Small Cell Lung Cancer | Jan 2027Pb-DOTAM-GRPR1 · Phase 1 | — | — | — | — |
| 1 asset: 1 Ph 1 | Leucettinib-21Phase 1 · Alzheimer's DiseaseWeak signal | None on record | — | — | — | — | |
Pierre Fabre MedicamentPrivate | 7 assets: 3 approved, 3 Ph 2, 1 Ph 1 | ElticertinibPhase 1/2 · Non-Small Cell Lung Cancer | 31 Mar 2027Binimetinib · Phase 3 | — | — | — | — |
ServierPrivate | 6 assets: 2 approved, 2 Ph 3, 2 Ph 2 | TeneligliptinPhase 3 · Type 2 DiabetesReliable signal | 31 Dec 2026Ivosidenib · Phase 1 | — | — | — | — |
TherAguixPrivate | 1 asset: 1 Ph 2 | AGuIXPhase 1/2 · Non-Small Cell Lung Cancer | None on record | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.